<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01591733</url>
  </required_header>
  <id_info>
    <org_study_id>11-328</org_study_id>
    <nct_id>NCT01591733</nct_id>
  </id_info>
  <brief_title>FOLFIRINOX + RT for Pancreatic Cancer</brief_title>
  <official_title>Phase II Study of Preoperative FOLFIRINOX Followed by Accelerated Short Course Radiation Therapy for Borderline-Resectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is a Phase II clinical trial. Phase II clinical trials test the
      effectiveness of a therapy to learn whether the therapy works in treating a specific cancer.
      &quot;Investigational&quot; means that the therapy is still being studied and that research doctors are
      trying to find out more about it-such as the safest dose to use, the side effects it may
      cause, and if therapy is effective for treating different types of cancer. Proton beam
      radiation therapy is an FDA (U.S. Food and Drug Administration) approved radiation delivery
      system.

      Proton beam radiation therapy is known to spare surrounding normal tissues from radiation as
      it delivers less radiation beyond the area of the target tissues. This may reduce side
      effects that patients would normally experience with standard (photon) radiation therapy,
      which tends to include more normal tissue along with tumor target tissue.

      Researchers in the laboratory have discovered that there are pathways inside the cells that
      can lead to growth and survival of the tumor. The chemotherapy drugs FOLFIRINOX and
      capecitabine are targeted towards blocking the pathways that allow cancer cells to divide,
      and may result in the tumor shrinking in size.

      In this research study, the investigators are looking to determine if proton beam radiation
      in combination with FOLFIRINOX and capecitabine is effective in controlling the growth of
      your cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For weeks 1-8, you will only be receiving FOLFIRINOX via IV infusion. The treatment plan will
      begin with four cycles (8 weeks) of FOLFIRINOX. Each cycle is 14 days long. You will receive
      FOLFIRINOX therapy on days 1, 2 and 3 of each of the four cycles. The FOLFIRINOX treatment is
      broken up into three different drugs. 5-FU will be administered over two hours on day one of
      each cycle, and then continuously with a pump for days 2 and 3. Oxaliplatin will be delivered
      by intravenous (infusion) over 120 minutes. Irinotecan will be given by IV for 90 minutes.
      All parts of this treatment will be received as an outpatient.

      If after 4 cycles of FOLFIRINOX therapy, your tumor has not spread, you will receive a
      further 4 cycles of FOLFIRINOX. If after 8 total cycles of FOLFIRINOX your cancer is clearly
      resectable, you will proceed to phase 2 of treatment with capecitabine and radiation therapy.

      You will take tablets of capecitabine by mouth for a total of 10 days (Monday through Friday)
      during the two weeks after your FOLFIRINOX treatment.

      You will be given a drug diary for capecitabine which contains instructions on how to take
      the drug.

      Short course radiation: You will receive proton radiation treatment for five days (Monday
      through Friday) after your FOLFIRINOX treatment, during the time of your capecitabine
      treatment, or photon radiation for ten days (Monday through Friday for two weeks). You will
      also be assessed at least once during this treatment course for any side effects you may be
      experiencing.

      You will receive study radiation treatment as an outpatient at the Francis H. Burr Proton
      Center or the Clark Center for Radiation Oncology at the Massachusetts General Hospital
      Surgery is expected to occur approximately one to four weeks after completion of capecitabine
      therapy.

      After your surgery, you may receive additional chemotherapy at the discretion of your
      treating physician and be followed as per standard of care.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2012</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of R0 Resection</measure>
    <time_frame>Post-surgery (about 4 months post baseline)</time_frame>
    <description>The rate of R0 resection of patients with borderline-resectable adenocarcinoma of the head of the pancreas, along with borderline-resectable and resectable adenocarcinoma of the body and tail of the pancreas. R0 resection means that following surgery, no cancer cells are seen microscopically at the resection margin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Progression-Free Survival</measure>
    <time_frame>From the start of treatment until death or disease progression, median duration of follow-up of 14.7 months</time_frame>
    <description>The median progression free survival as measured from the start of treatment until the time of disease progression or death, whichever occurs first. Disease status was evaluated using RECIST (Response Evaluation Criteria in Solid Tumors). Disease progression is defined as having at least a 20% increase in the sum of the longest diameter (LD) of target lesion, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival</measure>
    <time_frame>From the start of treatment until the time of death, median duration of follow-up of 37.7 months</time_frame>
    <description>Median overall survival, as measured from the start of treatment until the time of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preoperative Toxicity of Grade 3 or Worse Related to FOLFIRINOX and Chemoradiation</measure>
    <time_frame>From the start of treatment until the end of chemoradiation, about 4 months</time_frame>
    <description>Frequency of grade 3 or greater adverse events deemed related to FOLFIRINOX+short course radiation therapy. Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE 4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Participants With Surgery Related Adverse Events</measure>
    <time_frame>At the time of surgery, 30 days post-surgery</time_frame>
    <description>The number of participants with surgery related any grade adverse events following pancreaticoduodenectomy or distal pancreatectomy after receiving preoperative FOLFIRINOX and preoperative short course radiation therapy. Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE 4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 Day Post-operative Mortality Rate</measure>
    <time_frame>30 days post surgery (about 6 months from baseline)</time_frame>
    <description>The number of participants that died within 30 days after undergoing pancreaticoduodenectomy or distal pancreatectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Pathologic Downstaging</measure>
    <time_frame>Baseline, Post surgery</time_frame>
    <description>To determine the rate of pathologic down-staging among participants that underwent pancreaticoduodenectomy or distal pancreatectomy. The pathologic downstaging rate is the proportion of patients with the primary tumor and nodes downstaged based on final pathology of the surgical specimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Control Rates</measure>
    <time_frame>From the start of treatment until the end of treatment with FOLFIRINOX, or until disease progression (median duration of follow-up of approximately 14 months)</time_frame>
    <description>The number of participants that achieved local control. Local control was evaluated using RECIST (Response Evaluation Criteria in Solid Tumors). Local Failure is defined as progression of the primary tumor, or to the reappearance of tumor at the primary site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Mutational Analysis Biomarkers</measure>
    <time_frame>2 years</time_frame>
    <description>To correlate mutational analysis biomarkers (SNaPSHOT assay) with response to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life, Symptom Burden, and Mood</measure>
    <time_frame>2 years</time_frame>
    <description>Patient-reported outcomes: We will use descriptive statistics to describe Quality of Life (QOL) (EORTC QLQ-C30), symptom burden (ESAS-r) and mood (HADS) for the entire study cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utilization of Health Services (Emergency Room, Hospital and Intensive Care Unit)</measure>
    <time_frame>2 years</time_frame>
    <description>Summary of the number of hospitalizations, intensive care unit (ICU) stays, emergency department (ED) stays, and palliative care use for the study population.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive the FOLFIRINOX regimen, followed by capecitabine and short course radiation therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRINOX</intervention_name>
    <description>Up to Eight-14 day cycles</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>5-FU</other_name>
    <other_name>Oxaliplatin</other_name>
    <other_name>Irinotecan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Orally, for 10 days</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Short Course Radiation</intervention_name>
    <description>Five or ten days</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>1-4 weeks after completion of capecitabine therapy</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cytologic or histologic proof pancreatic ductal carcinoma

          -  Borderline resectable

          -  Life expectancy of at least 3 months

          -  ECOG Performance Status ≤ 1

          -  Adequate organ and bone marrow function

          -  No treatment of other invasive cancers within the last 5 years with greater than 5%
             risk of recurrence at the time of eligibility screening. Carcinoma in-situ and basal
             cell carcinoma/squamous cell carcinoma of the skin are allowed

          -  &gt; 4 weeks since major surgery, excluding laparoscopy

        Exclusion Criteria:

          -  Evidence of metastatic disease

          -  Pregnant or breastfeeding

          -  Other serious uncontrolled medical conditions

          -  Prior chemotherapy, targeted/biologic therapy or radiation for treatment of the
             pancreatic tumor

          -  Prior systemic fluoropyrimidine therapy

          -  History of uncontrolled seizures, central nervous system disorders or psychiatric
             disability

          -  Individuals on cimetidine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theodore S Hong, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2012</study_first_submitted>
  <study_first_submitted_qc>May 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2012</study_first_posted>
  <results_first_submitted>March 2, 2018</results_first_submitted>
  <results_first_submitted_qc>March 28, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 30, 2018</results_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Theodore Sunki Hong</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Borderline resectable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FOLFIRINOX + Radiation</title>
          <description>All participants will receive the FOLFIRINOX regimen, followed by capecitabine and short course radiation therapy.
FOLFIRINOX: Up to Eight-14 day cycles
Capecitabine: Orally, for 10 days
Short Course Radiation: Five or ten days
Surgery: 1-4 weeks after completion of capecitabine therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FOLFIRINOX + Radiation</title>
          <description>All participants will receive the FOLFIRINOX regimen, followed by capecitabine and short course radiation therapy.
FOLFIRINOX: Up to Eight-14 day cycles
Capecitabine: Orally, for 10 days
Short Course Radiation: Five or ten days
Surgery: 1-4 weeks after completion of capecitabine therapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="46" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CA19-9 Level</title>
          <description>Cancer antigen 19-9 (CA 19-9) level</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;35 U/ml (Normal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥35 U/ml (elevated)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CEA Level</title>
          <description>Carcinoembryonic antigen level</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;3.4 ng/ml (normal)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥3.4 ng/ml (elevated)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pancreatic Tumor Site</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Head</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tail</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor Size</title>
          <units>Centimeters (cm)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.75" lower_limit="2.1" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vessel Involvement</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Venous</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Arterial</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Both</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of R0 Resection</title>
        <description>The rate of R0 resection of patients with borderline-resectable adenocarcinoma of the head of the pancreas, along with borderline-resectable and resectable adenocarcinoma of the body and tail of the pancreas. R0 resection means that following surgery, no cancer cells are seen microscopically at the resection margin.</description>
        <time_frame>Post-surgery (about 4 months post baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Eligible - FOLFIRINOX + Radiation</title>
            <description>The overall study population
All participants will receive the FOLFIRINOX regimen, followed by capecitabine and short course radiation therapy.
FOLFIRINOX: Up to Eight-14 day cycles
Capecitabine: Orally, for 10 days
Short Course Radiation: Five or ten days
Surgery: 1-4 weeks after completion of capecitabine therapy</description>
          </group>
          <group group_id="O2">
            <title>Resected Participants - FOLFIRINOX + Radiation</title>
            <description>The participants that were resected.
All participants will receive the FOLFIRINOX regimen, followed by capecitabine and short course radiation therapy.
FOLFIRINOX: Up to Eight-14 day cycles
Capecitabine: Orally, for 10 days
Short Course Radiation: Five or ten days
Surgery: 1-4 weeks after completion of capecitabine therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of R0 Resection</title>
          <description>The rate of R0 resection of patients with borderline-resectable adenocarcinoma of the head of the pancreas, along with borderline-resectable and resectable adenocarcinoma of the body and tail of the pancreas. R0 resection means that following surgery, no cancer cells are seen microscopically at the resection margin.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression-Free Survival</title>
        <description>The median progression free survival as measured from the start of treatment until the time of disease progression or death, whichever occurs first. Disease status was evaluated using RECIST (Response Evaluation Criteria in Solid Tumors). Disease progression is defined as having at least a 20% increase in the sum of the longest diameter (LD) of target lesion, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
        <time_frame>From the start of treatment until death or disease progression, median duration of follow-up of 14.7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FOLFIRINOX + Radiation</title>
            <description>All participants will receive the FOLFIRINOX regimen, followed by capecitabine and short course radiation therapy.
FOLFIRINOX: Up to Eight-14 day cycles
Capecitabine: Orally, for 10 days
Short Course Radiation: Five or ten days
Surgery: 1-4 weeks after completion of capecitabine therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression-Free Survival</title>
          <description>The median progression free survival as measured from the start of treatment until the time of disease progression or death, whichever occurs first. Disease status was evaluated using RECIST (Response Evaluation Criteria in Solid Tumors). Disease progression is defined as having at least a 20% increase in the sum of the longest diameter (LD) of target lesion, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" lower_limit="10.5">Upper bound is not defined due to skewed survival data (participants still surviving).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival</title>
        <description>Median overall survival, as measured from the start of treatment until the time of death.</description>
        <time_frame>From the start of treatment until the time of death, median duration of follow-up of 37.7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FOLFIRINOX + Radiation</title>
            <description>All participants will receive the FOLFIRINOX regimen, followed by capecitabine and short course radiation therapy.
FOLFIRINOX: Up to Eight-14 day cycles
Capecitabine: Orally, for 10 days
Short Course Radiation: Five or ten days
Surgery: 1-4 weeks after completion of capecitabine therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival</title>
          <description>Median overall survival, as measured from the start of treatment until the time of death.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7" lower_limit="19.4">Upper bound is not defined due to skewed survival data (participants still surviving).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preoperative Toxicity of Grade 3 or Worse Related to FOLFIRINOX and Chemoradiation</title>
        <description>Frequency of grade 3 or greater adverse events deemed related to FOLFIRINOX+short course radiation therapy. Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE 4).</description>
        <time_frame>From the start of treatment until the end of chemoradiation, about 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FOLFIRINOX + Radiation</title>
            <description>All participants will receive the FOLFIRINOX regimen, followed by capecitabine and short course radiation therapy.
FOLFIRINOX: Up to Eight-14 day cycles
Capecitabine: Orally, for 10 days
Short Course Radiation: Five or ten days
Surgery: 1-4 weeks after completion of capecitabine therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Preoperative Toxicity of Grade 3 or Worse Related to FOLFIRINOX and Chemoradiation</title>
          <description>Frequency of grade 3 or greater adverse events deemed related to FOLFIRINOX+short course radiation therapy. Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE 4).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Febrile neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated alkaline phosphatase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated AST/ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral neuropathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Participants With Surgery Related Adverse Events</title>
        <description>The number of participants with surgery related any grade adverse events following pancreaticoduodenectomy or distal pancreatectomy after receiving preoperative FOLFIRINOX and preoperative short course radiation therapy. Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE 4).</description>
        <time_frame>At the time of surgery, 30 days post-surgery</time_frame>
        <population>The participants that underwent surgery</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFIRINOX + Radiation</title>
            <description>All participants will receive the FOLFIRINOX regimen, followed by capecitabine and short course radiation therapy.
FOLFIRINOX: Up to Eight-14 day cycles
Capecitabine: Orally, for 10 days
Short Course Radiation: Five or ten days
Surgery: 1-4 weeks after completion of capecitabine therapy</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Participants With Surgery Related Adverse Events</title>
          <description>The number of participants with surgery related any grade adverse events following pancreaticoduodenectomy or distal pancreatectomy after receiving preoperative FOLFIRINOX and preoperative short course radiation therapy. Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE 4).</description>
          <population>The participants that underwent surgery</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.375" lower_limit="0.233" upper_limit="0.536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>30 Day Post-operative Mortality Rate</title>
        <description>The number of participants that died within 30 days after undergoing pancreaticoduodenectomy or distal pancreatectomy.</description>
        <time_frame>30 days post surgery (about 6 months from baseline)</time_frame>
        <population>The number of participants that underwent surgery</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFIRINOX + Radiation</title>
            <description>All participants will receive the FOLFIRINOX regimen, followed by capecitabine and short course radiation therapy.
FOLFIRINOX: Up to Eight-14 day cycles
Capecitabine: Orally, for 10 days
Short Course Radiation: Five or ten days
Surgery: 1-4 weeks after completion of capecitabine therapy</description>
          </group>
        </group_list>
        <measure>
          <title>30 Day Post-operative Mortality Rate</title>
          <description>The number of participants that died within 30 days after undergoing pancreaticoduodenectomy or distal pancreatectomy.</description>
          <population>The number of participants that underwent surgery</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Pathologic Downstaging</title>
        <description>To determine the rate of pathologic down-staging among participants that underwent pancreaticoduodenectomy or distal pancreatectomy. The pathologic downstaging rate is the proportion of patients with the primary tumor and nodes downstaged based on final pathology of the surgical specimen.</description>
        <time_frame>Baseline, Post surgery</time_frame>
        <posting_date>08/2018</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Local Control Rates</title>
        <description>The number of participants that achieved local control. Local control was evaluated using RECIST (Response Evaluation Criteria in Solid Tumors). Local Failure is defined as progression of the primary tumor, or to the reappearance of tumor at the primary site.</description>
        <time_frame>From the start of treatment until the end of treatment with FOLFIRINOX, or until disease progression (median duration of follow-up of approximately 14 months)</time_frame>
        <population>The first 5 participants treated who only received 4 cycles of FOLFIRINOX instead of 8 were not included in the analysis of local control.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFIRINOX + Radiation</title>
            <description>All participants will receive the FOLFIRINOX regimen, followed by capecitabine and short course radiation therapy.
FOLFIRINOX: Up to Eight-14 day cycles
Capecitabine: Orally, for 10 days
Short Course Radiation: Five or ten days
Surgery: 1-4 weeks after completion of capecitabine therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Local Control Rates</title>
          <description>The number of participants that achieved local control. Local control was evaluated using RECIST (Response Evaluation Criteria in Solid Tumors). Local Failure is defined as progression of the primary tumor, or to the reappearance of tumor at the primary site.</description>
          <population>The first 5 participants treated who only received 4 cycles of FOLFIRINOX instead of 8 were not included in the analysis of local control.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Mutational Analysis Biomarkers</title>
        <description>To correlate mutational analysis biomarkers (SNaPSHOT assay) with response to treatment</description>
        <time_frame>2 years</time_frame>
        <posting_date>08/2018</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life, Symptom Burden, and Mood</title>
        <description>Patient-reported outcomes: We will use descriptive statistics to describe Quality of Life (QOL) (EORTC QLQ-C30), symptom burden (ESAS-r) and mood (HADS) for the entire study cohort.</description>
        <time_frame>2 years</time_frame>
        <posting_date>01/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Utilization of Health Services (Emergency Room, Hospital and Intensive Care Unit)</title>
        <description>Summary of the number of hospitalizations, intensive care unit (ICU) stays, emergency department (ED) stays, and palliative care use for the study population.</description>
        <time_frame>2 years</time_frame>
        <posting_date>01/2019</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the start of treatment until 30 days after the end of treatment, about 6 months. Treatment is continued until disease progression, intercurrent illness that prevents further treatment, unacceptable adverse events, participant withdrawal, or until the treating investigator decides it is in the participants best interest.</time_frame>
      <desc>Adverse events were defined as any grade 3 or greater toxicity deemed to be possibly, probably, or definitely related to treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>FOLFIRINOX + Radiation</title>
          <description>All participants will receive the FOLFIRINOX regimen, followed by capecitabine and short course radiation therapy.
FOLFIRINOX: Up to Eight-14 day cycles
Capecitabine: Orally, for 10 days
Short Course Radiation: Five or ten days
Surgery: 1-4 weeks after completion of capecitabine therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Cardiac disorders - Other</sub_title>
                <counts group_id="E1" events="17" subjects_affected="9" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Eye disorders - Other</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Watering eyes</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="38" subjects_affected="18" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="187" subjects_affected="44" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="33" subjects_affected="16" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="114" subjects_affected="40" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="201" subjects_affected="43" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="12" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Fecal incontinence</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="57" subjects_affected="20" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="28" subjects_affected="17" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other</sub_title>
                <counts group_id="E1" events="54" subjects_affected="26" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Gastroparesis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Malabsorption</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="36" subjects_affected="20" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="217" subjects_affected="46" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Rectal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="73" subjects_affected="30" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Edema face</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="51" subjects_affected="18" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="258" subjects_affected="48" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="44" subjects_affected="28" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other</sub_title>
                <counts group_id="E1" events="39" subjects_affected="11" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders - Other</sub_title>
                <counts group_id="E1" events="28" subjects_affected="10" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="14" subjects_affected="4" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="16" subjects_affected="7" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Injury, poisoning and procedural complications - Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="43" subjects_affected="20" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="33" subjects_affected="10" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="31" subjects_affected="16" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Cholesterol high</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pancreatic enzymes decreased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="21" subjects_affected="11" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="163" subjects_affected="41" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="163" subjects_affected="45" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="69" subjects_affected="25" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="92" subjects_affected="20" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders - Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="10" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="72" subjects_affected="27" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="22" subjects_affected="12" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="28" subjects_affected="9" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="9" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="18" subjects_affected="11" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Concentration impairment</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="55" subjects_affected="24" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dysesthesia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="25" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="31" subjects_affected="14" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="243" subjects_affected="46" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Spasticity</sub_title>
                <counts group_id="E1" events="19" subjects_affected="8" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="70" subjects_affected="26" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="28" subjects_affected="15" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hallucinations</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="78" subjects_affected="32" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders - Other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="20" subjects_affected="10" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Urinary tract pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Urinary urgency</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Urine discoloration</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders - Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="34" subjects_affected="15" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="33" subjects_affected="14" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="11" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="18" subjects_affected="9" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="55" subjects_affected="19" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="16" subjects_affected="8" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia syndrome</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other</sub_title>
                <counts group_id="E1" events="51" subjects_affected="23" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="26" subjects_affected="16" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Theodore Hong</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-6050</phone>
      <email>TSHONG1@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

